Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company’s helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Plasma Tech Pionee | Apyx Medical's helium-based Renuvion technology offers unique advantages in surgical applications, with strong demand evident in growing handpiece revenues |
Financial Headwinds | Despite market challenges, Apyx maintains a healthy gross profit margin of 61.04%, though profitability remains elusive in the current fiscal yea |
Strategic Innovation | Explore Apyx's upcoming Ayon body contouring system, set to launch in 2025, potentially driving generator sales and meeting diverse surgeon needs |
Market Positioning | Delve into Apyx's efforts to navigate cosmetic surgery market headwinds, balancing flat revenue projections with opportunities for global expansion |
Metrics to compare | APYX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPYXPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.3x | −3.1x | −0.6x | |
PEG Ratio | −0.09 | −0.09 | 0.00 | |
Price/Book | 10.2x | 3.1x | 2.6x | |
Price / LTM Sales | 1.6x | 3.7x | 3.3x | |
Upside (Analyst Target) | 104.1% | 38.0% | 38.0% | |
Fair Value Upside | Unlock | 8.4% | 4.3% | Unlock |